Compounded Tirzepatide vs Zepbound

Compounded tirzepatide vs Zepbound at a glance

Tirzepatide is the active ingredient in both. Zepbound is the FDA-approved product with a label revised in August 2026 that fixes its indications, strengths, escalation schedule, and storage rules. Compounded tirzepatide describes a category of pharmacy-made products with no shared label and no FDA review.

The table separates the facts a buyer can verify. The Zepbound column comes from the label and from Lilly's own savings page. The compounded column comes from FDA's compounding pages, since each pharmacy's product can differ.

Is compounded tirzepatide the same as Zepbound?

No. A compounded drug is, in FDA's words, not FDA-approved, and the agency does not check its safety, effectiveness, or quality before it is sold. Zepbound passed that check as a specific product with specific excipients and containers. A compounded tirzepatide vial is a different product from a different maker, and a telehealth page that calls it generic Zepbound is describing something that does not exist.

FDA had received more than 730 adverse-event reports involving compounded tirzepatide as of May 31, 2026. Its September 2026 update describes doses that exceed the approved label, faster escalation than the label allows, miscalculated self-administered doses, and products that arrived warm. The Zepbound label, by contrast, ties every strength to a fixed volume and lists the exact excipients in each presentation.

The honest framing is that Zepbound has a reviewed identity and compounded tirzepatide has a pharmacy's word. That is a reason to ask harder questions, not a verdict on any individual pharmacy.

Who makes Zepbound and who compounds tirzepatide

Eli Lilly manufactures Zepbound. Compounded tirzepatide comes from a 503A pharmacy, which is state-licensed and compounds against individual prescriptions under state board oversight, or from a 503B outsourcing facility, which registers with FDA and follows current good manufacturing practice. FDA explains that the two operate under different quality standards.

FDA confirmed the tirzepatide shortage resolved on December 19, 2024, and its enforcement discretion ended on February 18, 2025 for 503A pharmacies and March 19, 2025 for 503B facilities. Under the April 2026 clarification, a 503A pharmacy may not regularly compound essentially copies of a commercially available approved drug, and a 503B facility may not use bulk tirzepatide because it is on neither the bulks list nor the shortage list. A telehealth program offering compounded tirzepatide in 2026 should say which facility fills the prescription and what makes it more than a copy of Zepbound.

How each one is dosed and stored

The Zepbound label starts every patient at 2.5 mg injected once weekly for four weeks, then moves to 5 mg, with further 2.5 mg steps after at least four weeks on the current dose. Maintenance doses for weight reduction are 5, 10, or 15 mg weekly, and 15 mg is the maximum. Single-dose pens and vials hold 0.5 mL and stay refrigerated at 36°F to 46°F, with up to 21 days allowed at up to 86°F. The KwikPen and multi-dose vial hold four 0.6 mL doses and are discarded 30 days after first use or after the fourth dose.

Compounded tirzepatide normally arrives as a multi-dose vial with a pharmacy-specific concentration. The prescriber writes the dose, and the patient draws it with a syringe. FDA's advice is to discard a multi-dose vial 28 days after first use and to use a new sterile needle each time. Telehealth Ledger does not publish syringe-unit or concentration conversions, because those numbers belong to the pharmacy label for the exact product shipped.

The Zepbound schedule is not a dosing guide for a compounded product. Do not switch between Zepbound and compounded tirzepatide without the prescriber and pharmacy confirming the product and concentration.

Where you buy Zepbound and where compounded tirzepatide is sold

Zepbound is filled at retail pharmacies with or without insurance, and Lilly sells it directly to self-pay patients through LillyDirect, where the KwikPen and single-dose vials ship to the home or are picked up at a Walmart pharmacy. A telehealth clinician can write the prescription, but the product is still Lilly's. Lilly's savings page says the prescriber may choose the single-dose pen, single-dose vial, or KwikPen.

Compounded tirzepatide is sold through telehealth programs that bundle the clinician visit with a partner pharmacy's vial. There is no manufacturer channel, so the program's checkout is the price list. FDA advises getting the prescription from a licensed clinician and filling it at a state-licensed pharmacy, and treating no-prescription sales as a red flag.

What Zepbound costs through Lilly and how compounded tirzepatide is priced

Lilly's savings page lists a self-pay starting price of $299 per month for a one-month prescription of the 2.5 mg KwikPen or four 2.5 mg single-dose vials, and notes that 2.5 mg is a starting dose rather than an approved maintenance dose. Regular KwikPen prices are $299 for 2.5 mg, $399 for 5 mg, $499 for 7.5 mg, and $699 for 10, 12.5, and 15 mg, with a $449 purchase offer on the four highest strengths that depends on timely refills. Trade coverage of Lilly's December 2025 announcement lists single-dose vials at $299 for 2.5 mg, $399 for 5 mg, and $449 for 7.5 through 15 mg through LillyDirect; the LillyDirect page itself blocked our request, so treat those vial figures as needing a live check.

With commercial insurance that covers the single-dose pen, the Zepbound savings card can bring a fill to as little as $25 per month with a $100 monthly cap, and an uncovered single-dose pen can be as low as $499. The card excludes Medicare and other government programs and expires December 31, 2026. Eligible Medicare Part D beneficiaries pay $50 through the Medicare GLP-1 Bridge, which covers the KwikPen but not the single-dose vial or pen. Compounded tirzepatide has no list price. The catalog module below shows current telehealth prices for compounded tirzepatide and Zepbound programs with their price basis and verification date.

What to ask a telehealth provider before choosing

Ask these questions before paying, and keep the written answers. A program that will not answer them is not ready to be compared on price.

• Is this FDA-approved Zepbound from Lilly, and in which presentation, or a compounded tirzepatide product?
• If compounded, which pharmacy makes it, is it a 503A pharmacy or 503B facility, and what is the concentration on the label?
• What does the monthly price include, and what is the continuing price after any introductory month?
• How is the vial shipped and kept cold, and what happens if it arrives warm or damaged?
• What are the written instructions for measuring a dose, and who do I call when a dose is missed?
• What is the cancellation and refund rule if the clinician does not prescribe?